Home › Compare › UBX vs JNJ

UBX vs JNJ: Dividend Comparison 2026

UBX yields 999.50% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 UBX wins by $18762502.86M in total portfolio value
10 years
UBX
UBX
● Live price
999.50%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18762502.88M
Annual income
$15,677,048,250,727.08
Full UBX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — UBX vs JNJ

📍 UBX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUBXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UBX + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
UBX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UBX
Annual income on $10K today (after 15% tax)
$84,957.52/yr
After 10yr DRIP, annual income (after tax)
$13,325,491,013,118.02/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, UBX beats the other by $13,325,491,012,414.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UBX + JNJ for your $10,000?

UBX: 50%JNJ: 50%
100% JNJ50/50100% UBX
Portfolio after 10yr
$9381251.45M
Annual income
$7,838,524,125,777.43/yr
Blended yield
83.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

UBX
Analyst Ratings
7
Buy
3
Hold
Consensus: Buy
Price Target
$2.50
+1149.4% upside vs current
Range: $1.00 — $4.00
Altman Z
-26.4
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UBX buys
0
JNJ buys
0
No recent congressional trades found for UBX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUBXJNJ
Forward yield999.50% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$18762502.88M ✓$20.0K
Annual income after 10y$15,677,048,250,727.08 ✓$827.78
Total dividends collected$18526733.01M ✓$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$2.50$228.73 ✓

Year-by-year: UBX vs JNJ ($10,000, DRIP)

YearUBX PortfolioUBX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$110,650$99,950.02$10,676$355.77+$100.0K → UBX
2$1,151,991$1,033,595.59$11,407$389.39+$1.14M → UBX
3$11,289,539$10,056,908.06$12,198$426.53+$11.28M → UBX
4$104,190,015$92,110,208.43$13,056$467.62+$104.18M → UBX
5$905,946,717$794,463,401.71$13,987$513.12+$905.93M → UBX
6$7,425,409,853$6,456,046,865.26$14,998$563.56+$7425.39M → UBX
7$57,399,102,727$49,453,914,184.22$16,098$619.52+$57399.09M → UBX
8$418,691,166,930$357,274,127,011.89$17,295$681.69+$418691.15M → UBX
9$2,883,602,458,699$2,435,602,910,084.79$18,599$750.82+$2883602.44M → UBX
10$18,762,502,881,535$15,677,048,250,727.08$20,022$827.78+$18762502.86M → UBX

UBX vs JNJ: Complete Analysis 2026

UBX — Stock

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Full UBX Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this UBX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UBX vs SCHDUBX vs JEPIUBX vs OUBX vs KOUBX vs MAINUBX vs ABBVUBX vs MRKUBX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.